Pharmaceutical stocks underperform S&P 500 by 10% over 6 months post-reform

If drug pricing reform passes, major pharmaceutical companies like Pfizer and Merck will face margin pressure. Investors are likely to price in regulatory risks, leading to relative underperformance compared to the broader market.

Implied probability (Yes)

65%